Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Camurus AB reported significant financial performance and advancements in its pharmaceutical endeavors in the first quarter of 2025.</li><li>As a leader in opioid dependence treatment, Camurus increased its foothold in key markets.</li><li>The company’s flagship product, Buvidal, continued to show robust sales growth across Europe and Australia, increasing by around 6% year-over-year at constant exchange rates.</li></ul>

Camurus AB reported significant financial performance and advancements in its pharmaceutical endeavors in the first quarter of 2025.As a leader in opioid dependence treatment, Camurus increased its foothold in key markets.The company’s flagship product, Buvidal, continued to show robust sales growth across Europe and Australia, increasing by around 6% year-over-year at constant exchange rates.

Camurus: Initiation of Coverage- Regulatory Wins

Sweden

Camurus AB is a research based pharmaceutical company. The Company develops and commercializes therapeutic medications to treat issues including cancer, endocrinology, pain, metabolic disease and drug addiction.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Camurus (CAMX SS)

Camurus: Initiation of Coverage- Regulatory Wins

Camurus AB reported significant financial performance and advancements in its pharmaceutical endeavors in the first quarter of 2025. As a leader...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)